**Meningiomas' Management: An Update of the Literature**

[73] Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481-2498.

[74] Huse JT, Diamond EL, Wang L, Rosenblum MK. Mixed glioma with molecularfeatures of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"? Acta

[75] Wilcox P, Li CC, Lee M, Shivalingam B, Brennan J, et al. Oligoastrocytomas: throw‐ ing the baby out with the bathwater? Acta Neuropathol. 2015;129:147-149. DOI:

[76] Bai H, Zou Y, Lee AM, Tang X, Zhang P, et al. Does morphological assessment have a role in classifying oligoastrocytoma as "oligodendroglial" vs. "astrocytic"? Histopa‐

[77] Cai J, Zhu P, Zhang C, Li Q, Wang Z, Li, et al. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. Oncotarget. 2016.

[78] Hewer E, Vajtai I, Dettmer MS, Berezowska S, Vassella E. Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas. Histopathology.

[79] Mellai M, Caldera V, Annovazzi L, Schiffer D. The distribution and significance of IDH mutation in gliomas. In: Lichtor T, editor. Evolution of the Molecular Biology of Brain Tumors and Therapeutic Implications. Rjieka, Croatia: InTech; 2013. pp. 299-342. [80] Bosone I, Cavalla P, Chiadò-Piat L, Vito ND, Schiffer D. Cyclin D1 expression in normal oligodendroglia and microglia cells: its use in the differential diagnosis of oligoden‐

[81] Prayson RA. Oligodendroglioma look-alikes: the histopathologic differential diagno‐ sis. In: Reeves C, editor. Oligodendrogliomas (ODs): Diagnosis, Outcomes and

Neuropathol. 2015;129:151-153. DOI: 10.1007/s00401-014-1359-y.

10.1007/s00401-014-1353-4.

360 Neurooncology - Newer Developments

thology. 2015. DOI: 10.1111/his.12891.

2016;68:272-278. DOI: 10.1111/his.12743.

drogliomas. Neuropathology. 2001;21:155-161.

Prognosis. New York: Nova Biomedical; 2016. pp. 83-118.

DOI: 10.18632/oncotarget.7650.

Giulia Cossu, Mahmoud Messerer, Fabrice Parker, Marc Levivier and Roy Thomas Daniel

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/62929

#### **Abstract**

Meningiomas are the most common primary intracranial tumors in the adult popula‐ tion [1]. They are generally considered benign lesions but after the 2007 WHO classifica‐ tion, the proportion of atypical meningiomas has steeply increased. Surgery is considered the mainstay of the treatment and a complete resection is considered curative in WHO grade I meningiomas. The role of adjuvant treatments like radiotherapy (stereotactic radiosurgery or conventional external beam irradiation) and chemotherapy in more aggressive cases is still discussed, above all in WHO grade II meningiomas. We would like to expose the most important advances in meningiomas' management in accord‐ ance with the recent literature evidences.

**Keywords:** meningioma, management, benign meningiomas, atypical meningioma, anaplastic meningioma, malignant meningioma, surgery, radiotherapy, chemothera‐ py
